Entyvio is a treatment for ulcerative colitis and Crohn’s disease that has been linked to Interstitial Lung Disease, shortness of breath, and other life-threatening breathing problems.
What You Can Do & How We Can Help
The Schmidt Firm, PLLC is currently accepting Entyvio induced injury cases in all 50 states. If you or somebody you know has been diagnosed with Interstitial Lung Disease after taking Entyvio, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
What is Entyvio?
Entyvio® (vedolizumab) is a medication for adults with moderate-to-severe ulcerative colitis or Crohn’s disease. It is manufactured by Takeda Pharmaceuticals and was approved by the FDA in May 2014.
How Does Entyvio Work?
Entyvio is administered intravenously to patients by a doctor. It works by preventing too many white blood cells from entering the intestines, which prevents inflammation and other symptoms of ulcerative colitis.
What is the Problem?
A growing number of Entyvio patients have developed a severe or life-threatening case of interstitial lung disease. Some patients only had a couple doses of Entyvio before they died of a severe lung injury, and yet the label on Entyvio fails to include any warnings about this side effect.
What is Interstitial Lung Disease?
Interstitial lung disease is an umbrella term for a large group of diseases that cause inflammation and scarring (fibrosis) of the lungs. Over time, the scar-tissue makes it harder and harder for the lungs to provide oxygen to the body.
Signs & Symptoms of Lung Disease
The symptoms of interstitial lung disease may include:
- Shortness of breath
- Dry cough
- Chest discomfort or pain
- Fatigue
- Low appetite or weight-loss
- Fingertips and toes may become wide and rounded (clubbing) due to low oxygen
- High blood pressure
- Respiratory failure
- Heart failure
- Death
Entyvio Label Fails To Warn Patients About Lung Disease
The problem is that the label on Entyvio does not include any warnings about the risk of lung disease. The reports are rare, but very serious — and the longer it takes a doctor to diagnose the condition, the higher the risk of severe, life-threatening complications or death.
Recent Reports Linking Entyvio and Lung Disease
- Pulmonary Manifestation of Crohn’s Disease Developed Under Treatment With Vedolizumab: 28-year-old man took Entyvio for ulcerative colitis and developed shortness of breath, dry cough, lung fibrosis and inflammation.
- Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis: 39-year-old man took Entyvio and developed an “acute severe interstitial lung injury.”
- New-Onset Diffuse Parenchymal Lung Disease in a 52-Year-Old Woman With Ulcerative Colitis: 52-year-old woman took Entyvio for 2 years and was diagnosed with parenchymal lung disease.
- Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report: A man in China died after taking 2 doses of Entyvio and developing interstitial lung disease.
- Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab: A patient with Crohn’s disease developed granulomatous lung disease during treatment with Entyvio. Furthermore, doctors suggested a way that Entyvio could potentially cause lung disease: “Our case may add evidence to the emerging theory that gut-selective biologic agents could lead to upregulation of some pro-inflammatory factors leading to the evolution of pulmonary disease.”
Lung Diseases Linked to Entyvio
- Interstitial lung disease
- Pulmonary fibrosis
- Lung fibrosis (scarring)
- Lung / pulmonary problems
- Pulmonary parenchymal disease
- Parenchymal lung disease
- Pulmonary granulomas
- Respiratory failure
Do I have an Entyvio Lawsuit?
The Schmidt Firm, PLLC is currently accepting Entyvio induced injury cases in all 50 states. If you or somebody you know has been diagnosed with Interstitial Lung Disease after taking Entyvio, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.
The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs' law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm's reputation for providing personal attention to each and every client we represent.
